Abstract：Objective: To study the effects of azithromycin combined with pulmicort respiratory aspiration on mycoplasma pneumoniae infection in children and its effect on immune function. Methods: 90 children with mycoplasma pneumonia diagnosed in our hospital were randomly divided into observation group and control group, 45 cases in each group. The observation group was treated with azithromycin and pulmicort Respiratory inhalation. The control group was treated with azithromycin alone. Observe and compared the time of complete disappearance of symptoms, changes in serum immunoglobulin (Ig) values, changes in T lymphocyte subsets, changes in hs-CRP and cytokines, and adverse events. occurrence in the two groups. Results: After treatment, the time of fever, cough, sputum, chest tightness, wheezing and lung tribal sounds disappeared in the observation group, which was significantly lower than that in the control group (P<0.05). The Ig values of the two groups were increased to varying degrees, and the increase in the observation group was significantly greater than that in the control group. The difference was statistically significant (P<0.05). After treatment, the levels of CD3+, CD4+, and CD4+/CD8+ increased in different degrees in both groups, and CD8+ decreased. The increase and decrease in the observation group were significantly greater than those in the control group, with a significant difference (P<0.05). The levels of hs-CRP and IL-6 in both groups were decreased, and the decrease in the observation group was significantly greater than that in the control group (P<0.05). Both groups had adverse reactions such as nausea, vomiting and abdominal pain, but the incidence of adverse reactions was significantly lower in the observation group than in the control group (P<0.05). Conclusion: Compared to azithromycin alone, the use of azithromycin combined with Pulmicort Respiratory Inhalation for the treatment of children with Mycoplasma pneumoniae infection can relieve the symptoms of children quickly disappear, and can improve the immune function of children with no serious adverse reactions. It is worth in clinical application.
袁玲,朱冠南,王红兵. 阿奇霉素联合普米克令舒雾化吸入治疗小儿肺炎支原体感染的疗效及对免疫功能的影响[J]. 河北医学, 2018, 24(12): 1969-1972.
YUAN Ling. Effects of Azithromycin Combined with Pulmicort Respiratory Aspiration on Mycoplasma Pneumoniae Infection in Children and ts Effect on Immune Function. HeBei Med, 2018, 24(12): 1969-1972.
[1] 赵胃胃,赵华,王鑫.儿童肺炎支原体肺炎发病机制的研究进展[J].中华临床医师杂志(电子版),2015,9(20):3759~3763. [2] 张建华,李艳华.儿童重症肺炎临床特征和诊断治疗[J].中华临床医师杂志(电子版),2013,7(13):5715~5718. [3] Mosdosi B , Nyul Z , Nagy A , et al. Severe acrocyanosis precipitated by cold agglutinin secondary to infection with Mycoplasma pneumoniae in a pediatric patient[J]. Croatian Medical Journal 2017 , 58 (6 ):424~430. [4] 何谭娴,黄建萍.小儿支原体肺炎治疗的研究进展[J].医学综述,2014,20(8):1432~1434. [5] 金瑄.肺炎支原体抗体联合超敏C反应蛋白检测在小儿支原体肺炎感染诊断中的临床价值[J].标记免疫分析与临床,2015,22(8):744~746. [6] 陈广道,梁少媛,冯柏潮.儿童支原体肺炎的临床表现和实验室检查及影像学特点分析[J].中国全科医学,2015,18(1):59~64. [7] 张泓,叶信予,徐晓刚,等.儿童呼吸道分离肺炎支原体药物敏感性分析[J].中国感染与化疗杂志,2015,15(1):63~66. [8] 王兰,吴良霞.儿童大环内酯类耐药肺炎支原体感染研究进展[J].上海交通大学学报(医学版),2015,35(5):780~784. [9] 马香,丁明杰,赵秀侠,等.不同胸部影像学表现的肺炎支原体肺炎儿童的肺功能变化特征[J].中国当代儿科杂志,2014,16(10):997~1000. [10] 雷婷婷,赵荣生.雾化吸入给药的临床应用现状及研究进展[J].临床药物治疗杂志,2016,14(3):1~5. [11] Pirozynski M, Hantulik P, Almgren-Rachtan A, et al. Evaluation of the efficiency of single-inhaler combination therapy with budesonide/formoterol fumarate in patients with bronchial asthma in daily clinical practice[J]. Adv Ther,2017, 34(12):2648~2660. .
2018, Vol. 24 
冀公网安备13080202000786号